Market Mover | Vaxcyte Shares Surge 36% After Positive Topline Data from 1/2 Study of VAX-31 Vaccine
Market Mover | Vaxcyte Shares Surge 36% After Positive Topline Data from 1/2 Study of VAX-31 Vaccine
September 3, 2024 - $Vaxcyte (PCVX.US)$shares surged 36.58% to $110.30 in pre-market trading on Tuesday. The company today announced positive topline results from the Phase 1/2 study evaluating the safety, tolerability and immunogenicity of VAX-31, the Company’s 31-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD), in 1,015 healthy adults aged 50 and older.
2024年9月3日- $Vaxcyte (PCVX.US)$股票在週二美股盤前交易中上漲36.58%,達到110.30美元。該公司今天宣佈了Phase 1/2研究的積極頂線結果,評估了VAX-31的安全性、耐受性和免疫原性,該疫苗是該公司的31價肺炎球菌結合疫苗(PCV)候選藥物,旨在預防侵襲性肺炎球菌感染(IPD),在1015名50歲及以上健康成年人中進行。
![](https://uspost.moomoo.com/news-editor-imgs/20240903/public/17253647383153915671247.png)
VAX-31 generated strong immune responses for all 31 strains of pneumococcus it targets. For the 20 strains it shares with Prevnar 20, VAX-31 met or exceeded immune response criteria at medium and high doses. For the additional 11 strains unique to VAX-31, it met all superiority criteria at all doses.
VAX-31針對31個肺炎球菌菌株產生了強有效的免疫反應。對於與Prevnar 20共有的20個菌株,VAX-31在中、高劑量下達到或超過了免疫反應標準。對於VAX-31獨有的11個菌株,它在所有劑量下均滿足了所有優勢標準。
Based on these promising results, Vaxcyte plans to move VAX-31 to a larger Phase 3 study by mid-2025, with results expected in 2026. The company aims to provide broader protection against pneumococcal disease in adults over 50, addressing an important public health need.
基於這些令人鼓舞的結果,Vaxcyte計劃在2025年中期將VAX-31進入更大規模的Phase 3研究,並預計在2026年公佈結果。該公司旨在爲50歲以上的成年人提供更廣泛的肺炎球菌疾病保護,滿足重要的公共健康需求。
About Vaxcyte
關於Vaxcyte
Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. The Company is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. VAX-31 is a Phase 3-ready 31-valent, carrier-sparing PCV being developed for the prevention of IPD in adults and infants and is the broadest-spectrum PCV candidate in the clinic today. VAX-24, the Company’s 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market and is currently being evaluated in a Phase 2 infant study. Both VAX-31 and VAX-24 are designed to improve upon the standard-of-care PCVs by covering the serotypes in circulation that are responsible for a significant portion of IPD and are associated with high case-fatality rates, antibiotic resistance and meningitis, while maintaining coverage of previously circulating strains that are currently contained through continued vaccination practice.
Vaxcyte是一家致力於疫苗創新的公司,致力於開發高保真疫苗以保護人類免受細菌性疾病的影響。該公司正在研發廣譜結合疫苗和新型蛋白疫苗,以預防或治療細菌感染性疾病。VAX-31是一種準備進入Phase 3試驗的31價,無載體PCV,專爲預防成年人和嬰兒的IPD,是目前臨床上最廣譜的PCV候選藥物。VAX-24是該公司的24價PCV候選藥物,設計覆蓋了市場上任何嬰兒PCV的更多血清型別,並且目前正在進行Phase 2嬰兒研究。VAX-31和VAX-24都旨在改進目前的標準護理PCV,覆蓋目前循環的那些導致重要部分IPD、耐藥性和腦膜炎的血清型別,同時保持對以前循環的菌株的覆蓋,這些菌株目前通過繼續接種實踐持續控制。
Related Reading: Press Release
相關閱讀:新聞發佈